Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-05

Clinical Trial Update: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) [Phase 2]

View source ↗

Summary

A Phase 2 study of Zetomipzomib (KZR-616) in patients with active lupus nephritis has been terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zetomipzomib (zetomipzomib)

Snippet

Sponsor: Kezar Life Sciences, Inc. | Conditions: Lupus Nephritis | Phase 2 | Status: TERMINATED | Results posted: 2025-12-05